Amgen Inc. (NASDAQ:AMGN) Shares Acquired by FCA Corp TX

FCA Corp TX grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,340 shares of the medical research company’s stock after purchasing an additional 149 shares during the quarter. Amgen makes up approximately 1.5% of FCA Corp TX’s portfolio, making the stock its 15th largest holding. FCA Corp TX’s holdings in Amgen were worth $4,780,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AMGN. Centricity Wealth Management LLC purchased a new position in shares of Amgen during the fourth quarter valued at approximately $25,000. Legacy Investment Solutions LLC purchased a new position in shares of Amgen during the third quarter valued at approximately $29,000. Synergy Investment Management LLC purchased a new position in shares of Amgen during the fourth quarter valued at approximately $34,000. Atala Financial Inc purchased a new position in Amgen during the fourth quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC purchased a new position in Amgen during the fourth quarter worth approximately $36,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP David M. Reese sold 8,711 shares of Amgen stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the transaction, the executive vice president now directly owns 62,147 shares in the company, valued at approximately $18,222,743.34. This trade represents a 12.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 over the last ninety days. Corporate insiders own 0.69% of the company’s stock.

Analyst Ratings Changes

AMGN has been the topic of a number of recent analyst reports. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Redburn Partners cut their price target on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Piper Sandler Companies reissued an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a research report on Thursday, January 2nd. Citigroup reissued a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Finally, Wells Fargo & Company reissued an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $314.04.

Amgen Trading Up 0.3 %

Amgen stock opened at $316.04 on Friday. The firm’s 50-day moving average is $297.24 and its 200-day moving average is $298.80. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market cap of $169.78 billion, a P/E ratio of 41.86, a PEG ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.01%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.